Download PDF
Am J Perinatol
DOI: 10.1055/a-2099-8758
Original Article

Severe Acute Respiratory Syndrome-Coronavirus-2 Antibody Status at the Time of Delivery and the Risk of Preeclampsia

Arianna S. Portmann-Baracco 
1   Department of Obstetrics and Gynecology, Cayetano Heredia University, Lima, Perú
,
Rodrigo G. Alcorta-Proaño
1   Department of Obstetrics and Gynecology, Cayetano Heredia University, Lima, Perú
,
Claudia Nuñez-Mochizaki
1   Department of Obstetrics and Gynecology, Cayetano Heredia University, Lima, Perú
,
Camille M. Webb
1   Department of Obstetrics and Gynecology, Cayetano Heredia University, Lima, Perú
2   Department of Maternal Fetal Medicine, University of Texas Medical Branch, Galveston, Texas
,
Juan Trelles
1   Department of Obstetrics and Gynecology, Cayetano Heredia University, Lima, Perú
,
Carlos Caparo
1   Department of Obstetrics and Gynecology, Cayetano Heredia University, Lima, Perú
,
Mauricio F. La Rosa
1   Department of Obstetrics and Gynecology, Cayetano Heredia University, Lima, Perú
2   Department of Maternal Fetal Medicine, University of Texas Medical Branch, Galveston, Texas
› Author Affiliations Funding None.
› Further Information
    Permissions and Reprints

Abstract

Objective Our objective was to evaluate the association between severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) serologic status in immunologically naive patients and the risk of preeclampsia at the time of delivery.

Study Design We conducted a retrospective cohort study of pregnant patients admitted to our institution from August 1 to September 30, 2020. We recorded maternal medical and obstetric characteristics and SARS-CoV-2 serologic status. Our primary outcome was the incidence of preeclampsia. Antibody testing was performed, and patients were classified into seropositive groups: immunoglobulin (Ig)G + , IgM + , or both IgG+ and IgM + . Bivariate and multivariable analyses were performed.

Results We included 275 patients that were negative for SARS-CoV-2 antibodies, and 165 that were positive. Seropositivity was not associated with higher rates of preeclampsia (p = 0.183) or with preeclampsia with severe features (p = 0.916) even after adjusting for maternal age >35, BMI ≥ 30, nulliparity, and previous history of preeclampsia, and type of serologic status. Previous preeclampsia had the greatest association with the development of preeclampsia (odds ratio [OR] = 13.40; 95% confidence interval [CI]: 4.98–36.09; p <  0.05) and with preeclampsia with severe features (OR = 5.46; 95% CI: 1.65–18.02; p < 0.05).

Conclusion We found that in an obstetric population, there was no association between SARS-CoV-2 antibody status and the risk of preeclampsia.

Key Points

  • Pregnant people with acute COVID-19 are at an increased risk of developing preeclampsia.

  • Seroconversion during pregnancy was not associated with an increased risk of preeclampsia.

  • Further study regarding the timing of infection and its association with preeclampsia is necessary.

Keywords

COVID-19 - SARS-CoV-2 - preeclampsia - pregnancy

Note

Poster presented at the SMFM's 42nd Annual Pregnancy Meeting, Society of Maternal Fetal Medicine, Virtual meeting, January 31–February 5, 2022.




Publication History

Received: 11 April 2022

Accepted: 22 May 2023

Accepted Manuscript online:
25 May 2023

Article published online:
26 June 2023

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Mortality analyses. Johns Hopkins Coronavirus Resource Center. [cited 2022 Feb20]. Available from: https://coronavirus.jhu.edu/data/mortality
    PubMed
  • 2 Schwalb A, Seas C. The COVID-19 pandemic in Peru: what went wrong?. Am J Trop Med Hyg 2021; 104 (04) 1176-1178
    CrossrefPubMedGoogle Scholar
  • 3 Zambrano LD, Ellington S, Strid P. et al; Update: characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status — United States, January 22–October 3, 2020. MMWR Morb Mortal Wkly Rep 2020; 69 (44) 1641-1647
    CrossrefPubMedGoogle Scholar
  • 4 Centro Nacional de Epidemiología, Prevención y Control de Enfermedades. Situación Epidemiológica de la Mortalidad Materna en el Perú. Viceministerio de Salud Pública. Ministerio de Salud. 2021. Accessed June 8, 2023 at: https://www.dge.gob.pe/portal/docs/tools/teleconferencia/2021/SE162021/03.pdf
    PubMed
  • 5 Gurol-Urganci I, Jardine JE, Carroll F. et al. Maternal and perinatal outcomes of pregnant women with SARS-CoV-2 infection at the time of birth in England: national cohort study. Am J Obstet Gynecol 2021; 225 (05) 522.e1-522.e11
    CrossrefPubMedGoogle Scholar
  • 6 Conde-Agudelo A, Romero R. SARS-CoV-2 infection during pregnancy and risk of preeclampsia: a systematic review and meta-analysis. Am J Obstet Gynecol 2022; 226 (01) 68-89.e3 [published online ahead of print, 2021 Jul 21]
    CrossrefPubMedGoogle Scholar
  • 7 Powe CE, Levine RJ, Karumanchi SA. Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation 2011; 123 (24) 2856-2869
    CrossrefPubMedGoogle Scholar
  • 8 Guevara-Ríos E, Espinola-Sánchez M, Carranza-Asmat C. et al. Anticuerpos anti-SARS-COV-2 en gestantes en un hospital nivel III de Perú. Rev. Peru. Ginecol. Obstet. 2020; 66 (03) 00002 Disponible en: Accessed June 08, 2023 at: http://www.scielo.org.pe/scielo.php?script=sci_arttext&pid=S2304-51322020000300002&lng=es DOI: 10.31403/rpgo.v66i2259.
    CrossrefPubMedGoogle Scholar
  • 9 Interim guidelines for covid-19 antibody testing [Internet]. Centers for Disease Control and Prevention. Centers for Disease Control and Prevention; [cited 2022Feb19]. Accessed June 08, 2023 at: https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-guidelines.html#print
    PubMed
  • 10 Sidiq Z, Hanif M, Dwivedi KK, Chopra KK. Benefits and limitations of serological assays in COVID-19 infection. Indian J Tuberc 2020; 67 (4S): S163-S166
    CrossrefPubMedGoogle Scholar
  • 11 Gestational Hypertension and Preeclampsia. Gestational hypertension and preeclampsia: ACOG Practice Bulletin, Number 222. Obstet Gynecol 2020; 135 (06) e237-e260
    CrossrefPubMedGoogle Scholar
  • 12 Phipps EA, Thadhani R, Benzing T, Karumanchi SA. Pre-eclampsia: pathogenesis, novel diagnostics and therapies. Nat Rev Nephrol 2019; 15 (05) 275-289 [published correction appears in Nat Rev Nephrol. 2019 Jun;15(6):386]
    CrossrefPubMedGoogle Scholar
  • 13 Sánchez Sixto E. Actualización en la epidemiología de la preeclampsia: update. Rev Peru Ginecol Obstet 2014; 60 (04) 309-320 Disponible en: Accessed June 08, 2023 at: http://www.scielo.org.pe/scielo.php?script=sci_arttext&pid=S2304-51322014000400007&lng=es
    CrossrefPubMedGoogle Scholar
  • 14 Pacheco-Romero J, Acosta O, Huerta D. et al. Genetic markers for preeclampsia in Peruvian women. Colomb Med (Cali) 2021; 52 (01) e2014437
    PubMedGoogle Scholar
  • 15 La Rosa M, Ludmir J. Manejo de la preeclampsia con elementos de severidad antes de las 34 semanas de gestación: nuevos conceptos. Rev Peru Ginecol Obstet 2014;60(04) Lima oct./dic
    PubMedGoogle Scholar
  • 16 Peche Dávila G. Preeclampsia con criterios de severidad como factor de riesgo para resultados maternoperinatales adversos Hospital Alberto Sabogal Sologuren 2014-2018. [Proyecto de Investigación]. Lima: Universidad de San Martín de Porres, Facultad de Medicina Humana; 2021: 41
    Google Scholar
  • 17 Di Mascio D, Khalil A, Saccone G. et al. Outcome of coronavirus spectrum infections (SARS, MERS, COVID-19) during pregnancy: a systematic review and meta-analysis. Am J Obstet Gynecol MFM 2020; 2 (02) 100107
    CrossrefPubMedGoogle Scholar
  • 18 Hansen JN, Hine J, Strout TD. COVID-19 and preeclampsia with severe features at 34-weeks gestation. Am J Emerg Med 2020; 39: 252.e3-252.e5 [published online ahead of print, 2020 Jun 25]
    CrossrefPubMedGoogle Scholar
  • 19 Antoun L, Taweel NE, Ahmed I, Patni S, Honest H. Maternal COVID-19 infection, clinical characteristics, pregnancy, and neonatal outcome: a prospective cohort study. Eur J Obstet Gynecol Reprod Biol 2020; 252: 559-562
    CrossrefPubMedGoogle Scholar
  • 20 Villar J, Ariff S, Gunier RB. et al. Maternal and neonatal morbidity and mortality among pregnant women with and without COVID-19 infection: The INTERCOVID multinational cohort study. JAMA Pediatr 2021; 175 (08) 817-826
    Google Scholar
  • 21 Qu J, Wu C, Li X. et al. Profile of immunoglobulin G and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020; 71 (16) 2255-2258
    CrossrefPubMedGoogle Scholar
  • 22 Hoffmann M, Kleine-Weber H, Schroeder S. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181 (02) 271-280.e8
    CrossrefPubMedGoogle Scholar
  • 23 Verma S, Carter EB, Mysorekar IU. SARS-CoV2 and pregnancy: an invisible enemy?. Am J Reprod Immunol 2020; 84 (05) e13308 [published online ahead of print, 2020 Jul 17]
    CrossrefPubMedGoogle Scholar
  • 24 Egerup P, Fich Olsen L, Christiansen AH. et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies at delivery in women, partners, and newborns. Obstet Gynecol 2021; 137 (01) 49-55
    CrossrefPubMedGoogle Scholar
  • 25 Crovetto F, Crispi F, Llurba E. et al. Impact of SARS-CoV-2 infection on pregnancy outcomes: a population-based study. Clin Infect Dis 2021; 73 (10) 1768-1775 [published online ahead of print, 2021 Feb 8]
    CrossrefPubMedGoogle Scholar
  • 26 Khalil A, Samara A, Chowdhury T, O'Brien P. Does COVID-19 cause pre-eclampsia?. Ultrasound Obstet Gynecol 2022; 59 (02) 146-152
    CrossrefPubMedGoogle Scholar
  • 27 Rosenbloom JI, Raghuraman N, Carter EB, Kelly JC. Coronavirus disease 2019 infection and hypertensive disorders of pregnancy. Am J Obstet Gynecol 2021; 224 (06) 623-624
    CrossrefPubMedGoogle Scholar
  • 28 Meireles P, Amaro J, Pinto da Costa J. et al. Prevalence of SARS-CoV-2 antibodies among workers of the public higher education institutions of Porto, Portugal: a cross-sectional study. Occup Environ Med 2021; 78 (09) 648-653
    CrossrefPubMedGoogle Scholar